Joint Assessment on Ramucirumab (Cyramza®) in combination with Paclitaxel as second-line treatment for adult patients with advanced gastric or gastro-oesophageal junction adenocarcinoma

The purpose of the assessment is to evaluate Ramucirumab (Cyramza®) in combination with Paclitaxel for the treatment of gastric cancer. Final version of the assessment was published in March 2015 Below is the documentation provided by the Joint Assessment authoring team: WP5-SA-4_RAMUCIRUMAB for the treatment of gastric cancer_APPENDIX_6_INCLUDED Ramucirumab for the treatment of gastric cancer_Rapid […]

Joint Assessment on sorafenib (Nexavar®) and its use for the treatment of progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma refractory to radioactive iodine

The purpose of the assessment is to evaluate sorafenib Nexavar® and its use as a treatment of thyroid carcinoma Final version of the assessment was published in March 2015 Below is the documentation provided by the Joint Assessment authoring team:   Sorafenib for the treatment of thyroid carcinoma_Rapid REA_Final_Mar 2015_0